Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: a multicenter retrospective study of the Korean Cancer Study Group (KCSG)

BACKGROUND: There is no clear consensus on the recommended second-line treatment for patients with metastatic pancreatic cancer who have disease progression following gemcitabine-based therapy. We retrospectively evaluated the clinical outcomes of liposomal irinotecan (nal-IRI) plus fluorouracil/leu...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, H.S., Kang, B., Chon, H.J., Im, H.-S., Lee, C.-K., Kim, I., Kang, M.J., Hwang, J.E., Bae, W.K., Cheon, J., Park, J.O., Hong, J.Y., Kang, J.H., Kim, J.H., Lim, S.H., Kim, J.W., Kim, J.-W., Yoo, C., Choi, H.J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7878976/
https://www.ncbi.nlm.nih.gov/pubmed/33578192
http://dx.doi.org/10.1016/j.esmoop.2021.100049

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7878976/
https://www.ncbi.nlm.nih.gov/pubmed/33578192
http://dx.doi.org/10.1016/j.esmoop.2021.100049

Ejemplares similares